Patrick Bryant

Can molecular glues be designed rather than discovered by chance? We built EvoBind-multimer to design small (6-10 AAs) cyclic peptide glues directly from protein sequences. We validate de novo VHL-KRAS and VHL-BRD4 glues in cells and patient-derived tumoroids.

Introducing The Structural History of Eukarya (SHE): The first proteome-scale phylogeny constructed entirely from 3D structure. We computed 300 trillion alignments across 1,542 species to map the tree of life. 🧵👇 (1/5)

🕊️ Structural Acceleration Does a bigger genome mean faster structural evolution? No. We found lineage-specific bursts of structural innovation in Birds (Aves) and Ants (Hymenoptera) that are distinct from genomic expansion. (4/5)

Introducing The Structural History of Eukarya (SHE): The first proteome-scale phylogeny constructed entirely from 3D structure. We computed 300 trillion alignments across 1,542 species to map the tree of life. 🧵👇 (1/5)

🐁 Stop guessing your model organism. Our new search engine allows you to rank model organisms by their structural fidelity to specific human pathways. Case Study: For Fanconi Anaemia, Mouse is perfect. Yeast fails. C. elegans is a hidden gem. (2/5)

Our study where we develop EvoBind2: Design of linear and cyclic peptide binders from protein sequence information is now published! www.nature.com/articles/s42...

Now published: our study on human-pathogen protein-protein interactions! We identify 30 interactions with an expected TM-score ≥0.9, tripling the structural coverage in these networks. One novel interaction was validated with mass spectrometry. journals.plos.org/ploscompbiol...

Happy to release our breakthrough AI-model: RareFold, which predicts and designs proteins with noncanonical AAs. With EvoBindRare, we designed linear & cyclic peptide binders with high affinity & novel binding modes, wet lab validated. 📄 biorxiv.org/content/10.1... 💻 github.com/patrickbryan...

Happy to release our breakthrough AI-model: RareFold, which predicts and designs proteins with noncanonical AAs. With EvoBindRare, we designed linear & cyclic peptide binders with high affinity & novel binding modes, wet lab validated. 📄 biorxiv.org/content/10.1... 💻 github.com/patrickbryan...

Just like we have used EvoBind to e.g. create functional HIV inhibitors in a single shot (biorxiv.org/content/10.1...) we can now do this with an expanded vocabulary to have more chemical possibilities and avoid e.g. immune recognition and degradation

Happy to release our breakthrough AI-model: RareFold, which predicts and designs proteins with noncanonical AAs. With EvoBindRare, we designed linear & cyclic peptide binders with high affinity & novel binding modes, wet lab validated. 📄 biorxiv.org/content/10.1... 💻 github.com/patrickbryan...